Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1605, USA.
Expert Rev Anti Infect Ther. 2011 Jan;9(1):13-7. doi: 10.1586/eri.10.152.
Oropharyngeal candidiasis is a commonly encountered problem in daily clinical practice. Topical therapies for oropharyngeal candidiasis are considered preferable to systemic therapies in most patient populations. However, traditional topical therapies have limitations including short contact time with the oral mucosa and the need for multiple doses each day. Miconazole mucoadhesive tablet has recently been approved in Europe (Loramyc®) and the USA (Oravig™) for the treatment of oropharyngeal candidiasis. This tablet adheres to the oral mucosa and provides sustained local release of miconazole over a period of several hours with just one daily application. This article reviews the pharmacology, safety and efficacy of this novel agent.
口咽念珠菌病是日常临床实践中常见的问题。在大多数患者群体中，口咽念珠菌病的局部治疗被认为优于全身治疗。然而，传统的局部治疗方法存在一些局限性，包括与口腔黏膜接触时间短和每天需要多次给药。咪康唑粘膜粘附片最近已在欧洲（Loramyc®）和美国（Oravig™）获得批准，用于治疗口咽念珠菌病。该片剂粘附于口腔黏膜，并在数小时内持续局部释放咪康唑，每天只需应用一次。本文综述了这种新型制剂的药理学、安全性和疗效。
